Bimekizumab (anti-IL17A&IL-17F) (C007B-552703)

Bimekizumab (anti-IL17A&IL-17F) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab (anti-IL17A&IL-17F) blocks the inflammation-driven osteogenic differentiation.Purity≥95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg

Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot

Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/AB182793-SCI_31c472c3cc34d4e88d8d9fe7b566d353.pdf

UPC:

51201569

Condition:

New

Weight:

0.07 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

Ab182793-100μg

CAS:

1418205-77-2

Product Size:

100μg